ABSTRACT
In a multicentre, double-masked, randomized, placebocontrolled trial, outpatients in the secondary progressive phase of multiple sclerosis, having scores of 3.0-6.5 on the Expanded Disability Status Scale (EDSS), received either 8 million IU interferon b-1b every other day subcutaneously,
Note that for answers to extended matching items (EMIs), each option (denoted a, b, c, etc.) might be used once, more than once or not at all. For multiple-choice questions (MCQs), please select the best answer.
